Zoetis Inc. (NYSE:ZTS) issued an update on its FY17 earnings guidance on Thursday morning. The company provided EPS guidance of $2.34-$2.39 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.34. The company issued revenue guidance of $5.225-$5.275 billion, compared to the consensus revenue estimate of $5.20 billion.
Zoetis Inc. (NYSE:ZTS) traded down $0.17 during mid-day trading on Friday, hitting $69.13. The stock had a trading volume of 1,905,700 shares, compared to its average volume of 2,817,385. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The stock has a market capitalization of $33,769.08, a price-to-earnings ratio of 31.79, a PEG ratio of 2.03 and a beta of 1.02. Zoetis Inc. has a 1-year low of $48.24 and a 1-year high of $70.48.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.52 earnings per share. equities research analysts forecast that Zoetis Inc. will post 2.36 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be given a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.61%. Zoetis’s payout ratio is 22.11%.
A number of research analysts have commented on ZTS shares. Zacks Investment Research upgraded Zoetis from a hold rating to a buy rating and set a $71.00 price target on the stock in a research note on Thursday, October 12th. Cantor Fitzgerald restated a buy rating and set a $75.00 price target on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub cut Zoetis from a hold rating to a sell rating in a research note on Friday, October 6th. Morgan Stanley upped their price target on Zoetis from $61.00 to $70.00 and gave the stock an equal weight rating in a research note on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) restated a neutral rating and set a $62.00 price target on shares of Zoetis in a research note on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. Zoetis presently has an average rating of Buy and a consensus target price of $67.06.
TRADEMARK VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/zoetis-inc-zts-releases-fy17-earnings-guidance.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.